Quarterly Report · 10-Q
Seer, Inc.
SEERNASDAQEQUITYCurrent
Quarterly Report
Company context
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.
Current securities
Recent company filings
- 10-Q filingNov 10, 2026
- Results of Operations and Financial ConditionNov 10, 2026
- SCHEDULE 13D - filed by BML Investment Partners, L.P. regarding Seer, Inc.Nov 2, 2026
- Other EventsOct 29, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 18, 2026
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗